Prothrombinase induced clotting time (PiCT®) for measuring the activity of direct factor Xa inhibitors in clinical setting

被引：0
|
作者：
Olivera, P. E. [1 ]
Cortina, V [1 ]
Pons, V [1 ]
Merchan, B. [2 ]
Lopez-Andreoni, L. [1 ]
Artaza, G. [1 ]
Menino, E. [3 ]
Marin, A. [2 ]
Bosch, F. [2 ]
Santamaria, A. [1 ]
机构：
[1] Univ Hosp Vall dHebron, Hemostasis & Thrombosis Unit, Barcelona, Spain
[2] Univ Hosp Vall dHebron, Dept Hematol, Barcelona, Spain
[3] Primary Healthcare Ctr Rio de Janeiro Prosperitat, Barcelona, Spain
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO375-TUE
引用
收藏
页码：643 / 643
页数：1
相关论文
共 50 条
  • [31] Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time
    de Denus, S
    Spinler, SA
    PHARMACOTHERAPY, 2002, 22 (04): : 433 - 435
  • [32] Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors
    Ono, Ryohei
    Nishimura, Kazutaka
    Takahashi, Hidehisa
    Hori, Yasuhiko
    Fukushima, Kenichi
    Kobayashi, Yoshio
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (02) : 323 - 336
  • [33] Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors
    Ryohei Ono
    Kazutaka Nishimura
    Hidehisa Takahashi
    Yasuhiko Hori
    Kenichi Fukushima
    Yoshio Kobayashi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 323 - 336
  • [34] Editorial Comment: Oral Factor Xa and Direct Thrombin Inhibitors: A Clinical Perspective
    Gamelli, Richard L.
    JOURNAL OF BURN CARE & RESEARCH, 2012, 33 (04): : 462 - 462
  • [35] Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
    Steffel, Jan
    Luescher, Thomas F.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2009, 10 (08) : 616 - 623
  • [36] Recent advances in clinical trials of the direct and indirect selective Factor Xa inhibitors
    Porcari, AR
    Chi, L
    Leadley, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (07) : 1595 - 1600
  • [37] Neutralization Of Hemorrhage Induced By Direct Factor Xa and Thrombin Inhibitors In a Rat Model
    Jeske, Walter
    Escalante, Vicki
    McGuire, Brian
    Walenga, Jeanine M.
    Fareed, Jawed
    Bakhos, Mamdouh
    BLOOD, 2013, 122 (21)
  • [38] Clinical and laboratory validation of the 2nd International Standard of low molecular weight heparin (IS 2003-01/608) in the anti-Xa. Anti-LIA heptest and prothrombinase induced clotting (PiCT) tests
    Hoppensteadt, D
    Jeske, W
    Fareed, D
    Baltasar, F
    Walenga, JM
    Tobu, M
    Demir, M
    Iqbal, O
    Wahi, R
    Fareed, J
    BLOOD, 2005, 106 (11) : 117B - 117B
  • [39] Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity (vol 47, pg 1398, 2007)
    Graff, J.
    von Hentig, N.
    Misselwitz, F.
    Kubitza, D.
    Becka, M.
    Breddin, H. K.
    Harder, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11): : 1368 - 1368
  • [40] An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma
    Samama, Meyer Michel
    Amiral, Jean
    Guinet, Celine
    Perzborn, Elisabeth
    Depasse, Francois
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) : 1078 - 1079
12345